BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24743191)

  • 1. [Anti-angiogenic therapy for malignant glioma].
    Nagane M
    Gan To Kagaku Ryoho; 2014 Feb; 41(2):141-7. PubMed ID: 24743191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel anti-angiogenic therapies for malignant gliomas.
    Norden AD; Drappatz J; Wen PY
    Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab in high-grade gliomas: past, present, and future.
    Curry RC; Dahiya S; Alva Venur V; Raizer JJ; Ahluwalia MS
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):387-97. PubMed ID: 25797685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab for the treatment of high-grade glioma.
    Khasraw M; Simeonovic M; Grommes C
    Expert Opin Biol Ther; 2012 Aug; 12(8):1101-11. PubMed ID: 22663137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab for the treatment of glioblastoma.
    Chowdhary S; Chamberlain M
    Expert Rev Neurother; 2013 Aug; 13(8):937-49. PubMed ID: 23952194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.
    Hofer S; Elandt K; Greil R; Hottinger AF; Huber U; Lemke D; Marosi C; Ochsenbein A; Pichler J; Roelcke U; Weder P; Zander T; Wick W; Weller M
    Acta Oncol; 2011 Jun; 50(5):630-5. PubMed ID: 21495907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving strategies: future treatment of glioblastoma.
    Chamberlain M
    Expert Rev Neurother; 2011 Apr; 11(4):519-32. PubMed ID: 21469925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on bevacizumab and other angiogenesis inhibitors for brain cancer.
    Rinne ML; Lee EQ; Nayak L; Norden AD; Beroukhim R; Wen PY; Reardon DA
    Expert Opin Emerg Drugs; 2013 Jun; 18(2):137-53. PubMed ID: 23668489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas.
    Chamberlain MC
    Cancer; 2010 Sep; 116(17):3988-99. PubMed ID: 20564141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas.
    Argyriou AA; Giannopoulou E; Kalofonos HP
    Oncology; 2009; 77(1):1-11. PubMed ID: 19439998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab does not increase the risk of remote relapse in malignant glioma.
    Wick A; Dörner N; Schäfer N; Hofer S; Heiland S; Schemmer D; Platten M; Weller M; Bendszus M; Wick W
    Ann Neurol; 2011 Mar; 69(3):586-92. PubMed ID: 21446027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic Therapy of High-Grade Gliomas.
    Jo J; Wen PY
    Prog Neurol Surg; 2018; 31():180-199. PubMed ID: 29393186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab in glioblastoma multiforme.
    Specenier P
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):9-18. PubMed ID: 22149428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chemotherapy for malignant gliomas: an update].
    Wakabayashi T; Natsume A; Fujii M
    Gan To Kagaku Ryoho; 2013 Oct; 40(10):1283-7. PubMed ID: 24105052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenic inhibition in high-grade gliomas: past, present and future.
    Jo J; Schiff D; Purow B
    Expert Rev Neurother; 2012 Jun; 12(6):733-47. PubMed ID: 22650175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
    Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence.
    Wick W; Wick A; Weiler M; Weller M
    Curr Neurol Neurosci Rep; 2011 Jun; 11(3):305-12. PubMed ID: 21279815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response.
    Tamura R; Tanaka T; Miyake K; Yoshida K; Sasaki H
    Brain Tumor Pathol; 2017 Apr; 34(2):62-77. PubMed ID: 28386777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of bevacizumab for the treatment of glioblastoma.
    Yu Z; Zhao G; Zhang Z; Li Y; Chen Y; Wang N; Zhao Z; Xie G
    Exp Ther Med; 2016 Feb; 11(2):371-380. PubMed ID: 26893618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic therapy for high-grade gliomas: current concepts and limitations.
    De Bonis P; Marziali G; Vigo V; Peraio S; Pompucci A; Anile C; Mangiola A
    Expert Rev Neurother; 2013 Nov; 13(11):1263-70. PubMed ID: 24175724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.